Abstract is: Insulin glargine, sold under the brand name Lantus among others, is a long-acting modified form of medical insulin, used in the management of type I and type II diabetes. It is typically the recommended long acting insulin in the United Kingdom. It is used once a day as an injection just under the skin. Effects generally begin an hour after use. Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain. Other serious side effects include low blood potassium. NPH insulin rather than insulin glargine is generally preferred in pregnancy. After injection microcrystals slowly release insulin for about 24 hours. This insulin causes body tissues to absorb glucose from the blood and decreases glucose production by the liver. Insulin glargine was approved for medical use in the United States in 2000. It is on the World Health Organization's List of Essential Medicines. In 2020, it was the 32nd most commonly prescribed medication in the United States with more than 17 million prescriptions. In July, 2021 the United State Food and Drug administration (FDA) approved an "interchangeable biosimilar insulin product" called Semglee (insulin glargine yfgn) for the treatment of diabetes. This product costs a fraction of Lantus per dose, and has also been approved for use in other animals including cats and dogs.
| medication | Q12140 |
| biopharmaceutical | Q679692 |
| protein | Q8054 |
| Insulin/IGF/Relaxin family | Q24766924 |
| P267 | ATC code | A10AE04 |
| P8072 | CAB ID | 188344 |
| P231 | CAS Registry Number | 160337-95-1 |
| P592 | ChEMBL ID | CHEMBL1201497 |
| P661 | ChemSpider ID | 35033175 |
| P9272 | DeCS ID | 55956 |
| P3117 | DSSTox substance ID | DTXSID0043927 |
| P232 | EC number | 810-906-5 |
| P2566 | ECHA Substance Infocard ID | 100.241.126 |
| P9635 | electronic Essential Medicines List medicine ID | 573 |
| P646 | Freebase ID | /m/05qxx3 |
| P595 | Guide to Pharmacology Ligand ID | 7572 |
| P235 | InChIKey | COCFEDIXXNGUNL-RFKWWTKHSA-N |
| P665 | KEGG ID | D03250 |
| P10245 | MedlinePlus drug identifier | a600027 |
| P486 | MeSH descriptor ID | D000069036 |
| P672 | MeSH tree code | D06.472.699.587.200.300.100 |
| D12.644.548.586.200.300.100 | ||
| P6366 | Microsoft Academic ID | 2779920387 |
| P2115 | NDF-RT ID | N0000148667 |
| P10283 | OpenAlex ID | C2779920387 |
| P4235 | PatientsLikeMe treatment ID | insulin-glargine |
| P638 | PDB structure ID | 4IYD |
| 4IYF | ||
| P11199 | Probes And Drugs ID | PD155004 |
| P662 | PubChem CID | 118984454 |
| 44146714 | ||
| P3345 | RxNorm ID | 274783 |
| P2892 | UMLS CUI | C0907402 |
| P652 | UNII | 2ZM8CX04RZ |
| P11143 | WikiProjectMed ID | Insulin glargine |
| P3780 | active ingredient in | Abasaglar | Q28977410 |
| Lantus | Q29006109 | ||
| Lusduna | Q29006148 | ||
| Toujeo | Q29006583 | ||
| Basaglar | Q48828086 | ||
| P2067 | mass | 6060.825117 | |
| P2175 | medical condition treated | type-1 diabetes | Q124407 |
| hyperglycemia | Q271993 | ||
| maturity-onset diabetes of the young type 2 | Q32147145 | ||
| P3489 | pregnancy category | US pregnancy category C | Q28123617 |
| P2868 | subject has role | anti-diabetic medication | Q575062 |
FileName: Toujeo 300 IU-ml inj.jpg
Description: Toujeo, proprietary medicinal product, 1 ml contains 300 IU of insulin glargine. Manufacturer Sanofi.
Artist: Tomino de WS
Work is copyrighted.
License: CC BY-SA 4.0
Attribution is required.
| Q63590445 | A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) |
| Q100788366 | A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine |
| Q61933891 | A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus |
| Q63403725 | A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use |
| Q62031676 | A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week |
| Q63597944 | A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week |
| Q63595305 | A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes. |
| Q100789098 | A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before |
| Q113923864 | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (C |
| Q61924336 | A Study for Patients With Type 1 Diabetes Mellitus |
| Q63322152 | A Study in Adults With Type 1 Diabetes |
| Q63322091 | A Study in Adults With Type 2 Diabetes |
| Q61955896 | A Study in Participants With Type 2 Diabetes Mellitus |
| Q61938254 | A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) |
| Q61966613 | A Study in Participants With Type I Diabetes Mellitus |
| Q113893563 | A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes |
| Q113894009 | A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) |
| Q63573314 | A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk |
| Q99956129 | A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin |
| Q99956546 | A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes |
| Q61955460 | A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170) |
| Q61894227 | A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes |
| Q63320839 | A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants |
| Q113942735 | A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers |
| Q86302981 | A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes |
| Q63316791 | A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin |
| Q61979112 | An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006) |
| Q61914827 | Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes |
| Q113932351 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
| Q63336340 | Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM |
| Q63322507 | Comparing Long-acting Insulins During Exercise in Type 1 Diabetes |
| Q63578834 | Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus |
| Q62105264 | Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes |
| Q105089337 | Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose |
| Q63392984 | Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. |
| Q62105710 | Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes |
| Q61975899 | Comparison of Insulin Therapy in Treating Post-Transplant Diabetes |
| Q86172799 | Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (2009-09-30) |
| Q61938110 | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes |
| Q86172071 | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (2010-02-28) |
| Q86172096 | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (2010-03-31) |
| Q63587227 | Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine |
| Q61979153 | Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) |
| Q62104741 | Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents |
| Q113926649 | Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care |
| Q61918231 | DOMME Dose Optimization Multicentric Mexican Evaluation |
| Q113893195 | Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management |
| Q93947159 | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (2006-05-31) |
| Q61957223 | Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis |
| Q61957229 | Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure |
| Q63334383 | Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes |
| Q87931887 | Effects of Local Insulin on Varicose Ulcers for Wound Healing |
| Q63394883 | Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus |
| Q62041405 | Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) |
| Q63320802 | Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients |
| Q61894510 | Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes |
| Q63403128 | Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents |
| Q113917756 | Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes |
| Q61914862 | Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) |
| Q63401907 | Empagliflozin Effect on Glucose Toxicity |
| Q61957662 | Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use |
| Q63340819 | Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day |
| Q63319169 | FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) |
| Q61980726 | Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes |
| Q63321591 | Health Care for Type 1 Diabetes in Developing World |
| Q63322735 | Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study |
| Q63334142 | Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients |
| Q63534042 | Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) |
| Q61914681 | Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil) |
| Q113897411 | Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors |
| Q86246475 | Insulin Glargine in Type 2 Diabetes Mellitus (2005-04-30) |
| Q113917390 | Insulin for Hyperglycemia in Stroke Trial |
| Q89154392 | Intensive Glycemic Control For Diabetic Foot Ulcer Healing |
| Q61921705 | LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus |
| Q63335806 | Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment |
| Q61981287 | Levemir-Body Composition and Energy Metabolism |
| Q99081989 | Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus |
| Q113939173 | Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis |
| Q63336120 | Pharmacist Intervention for Glycemic Control in The Community |
| Q63404557 | Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL |
| Q61914868 | REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) |
| Q63402019 | Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin |
| Q63598831 | Remission Through Early Monitored Insulin Therapy - Duration Month |
| Q63335042 | Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus |
| Q63336638 | Safety of NNC 0123-0000-0338 in Healthy Subjects |
| Q63340321 | Satisfaction of Treatment Among Elderly Patients With Insulin Therapy |
| Q62062372 | Simplified Insulin Regimen for the Elderly |
| Q63320007 | Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus |
| Q62031623 | Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) |
| Q63063312 | Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes |
| Q61957102 | Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260) |
| Q99955970 | Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin |
| Q113893034 | The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus |
| Q63340574 | The Impact of Food on Blood Sugar in People With Type 2 Diabetes |
| Q61934172 | The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes |
| Q61922183 | This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus |
| Q63405409 | Toujeo Versus NPH Self-titration Study |
| Q63596308 | Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. |
| Q62820279 | Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia |
| Q61914394 | Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients |
| Q44698769 | 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes |
| Q37227385 | A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). |
| Q46696361 | A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes. |
| Q51552514 | A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. |
| Q40717578 | A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. |
| Q42607495 | A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes |
| Q88495294 | A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina |
| Q35748827 | A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). |
| Q36924024 | A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus |
| Q53862758 | A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes |
| Q89002572 | A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes |
| Q43068821 | A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus. |
| Q35772593 | A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine |
| Q89080788 | A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study |
| Q91060406 | A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes |
| Q58699251 | A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes |
| Q92343246 | A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease |
| Q55162068 | A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. |
| Q90420479 | A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide |
| Q35277018 | A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine |
| Q81527446 | A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication |
| Q90537112 | A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes |
| Q45151957 | A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study |
| Q38182669 | A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis |
| Q44706399 | A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine |
| Q51495383 | A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. |
| Q34981168 | A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. |
| Q47943212 | A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes |
| Q58763121 | A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study |
| Q51332542 | A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes. |
| Q51393129 | A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. |
| Q91049866 | A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada |
| Q42195355 | A cross-national comparison of 17 countries' insulin glargine drug labels |
| Q44827838 | A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir wit |
| Q92428823 | A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice |
| Q35021486 | A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus |
| Q41200024 | A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia |
| Q46886811 | A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro |
| Q58554943 | A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA) |
| Q38041660 | A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. |
| Q34583351 | A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial |
| Q37421683 | A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial |
| Q90856732 | A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine |
| Q46592253 | A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes |
| Q84466887 | A possible link between insulin glargine and malignancy : the facts: comment from Prof François Bonnici |
| Q37041205 | A possible link between insulin glargine and malignancy: the facts |
| Q64970098 | A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. |
| Q98165994 | A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control |
| Q51359123 | A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. |
| Q36449523 | A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes |
| Q36204211 | A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus |
| Q39619624 | A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. |
| Q34422997 | A randomized clinical trial comparing breakfast and bedtime administration of insulin glargine in children and adolescents with type 1 diabetes |
| Q42599961 | A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes |
| Q46879869 | A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen |
| Q40539633 | A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes |
| Q46602351 | A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes |
| Q86888890 | A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study) |
| Q51494744 | A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies |
| Q36249553 | A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency |
| Q36334537 | A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes |
| Q46734182 | A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes |
| Q44953969 | A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine |
| Q30978373 | A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine |
| Q39321463 | A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark |
| Q38386958 | Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes |
| Q86140328 | Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insu |
| Q50449409 | Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin |
| Q90710067 | Addendum to: The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol |
| Q44926596 | Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes |
| Q33853992 | Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes |
| Q37106467 | Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). |
| Q47179141 | Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration |
| Q35809936 | Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly |
| Q85154736 | Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial |
| Q46308233 | Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial |
| Q45332378 | Adoption of a new technology in a Veterans Affairs national formulary system with local implementation: the insulin glargine example |
| Q38811608 | Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes |
| Q51321430 | Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. |
| Q34613075 | Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes |
| Q48103815 | All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine. |
| Q104563848 | An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin glargine plus other oral hypoglycemic agents |
| Q51326336 | An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300. |
| Q40776543 | An Open-label Longitudinal Study on the Efficacy of Switching from Insulin Glargine or Detemir to Degludec in Type 2 Diabetes Mellitus |
| Q42910597 | An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence? |
| Q35207429 | An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia |
| Q35451514 | An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes |
| Q47429828 | An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin |
| Q51562266 | An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. |
| Q91037750 | An observational, multicentre study on different insulin glargine U100 titration algorithms used in patients with type 2 diabetes in daily medical practice in Adriatic countries: The ADRESA study |
| Q34906412 | An overview of insulin glargine |
| Q42618435 | Analytical and Biological Characterization of a Noninnovator Insulin Glargine and the Originator Drug Product |
| Q89349229 | Another insulin glargine (Basaglar) for diabetes |
| Q42508343 | Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients. |
| Q37286787 | Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial |
| Q58753011 | Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis |
| Q38620136 | Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes |
| Q52652735 | Authors' Reply to Dr. Riccardo Perfetti: "LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes". |
| Q58817846 | Authors’ Reply to Dr. Malerbi: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?” |
| Q41774550 | Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes |
| Q47647159 | Basal Insulin Peglispro Increases Lipid Oxidation, Metabolic Flexibility, Thermogenesis And Ketone Bodies Compared To Insulin Glargine In Subjects With Type 1 Diabetes Mellitus |
| Q51554474 | Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. |
| Q51323491 | Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. |
| Q46449114 | Basal insulin glargine vs prandial insulin lispro in type 2 diabetes |
| Q81733699 | Basal insulin glargine vs prandial insulin lispro in type 2 diabetes |
| Q51443441 | Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. |
| Q45945967 | Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. |
| Q37394470 | Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. |
| Q43584177 | Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin |
| Q64239470 | Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment |
| Q36426817 | Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials |
| Q46127825 | Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies |
| Q47830292 | Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. |
| Q42047899 | Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes |
| Q47253247 | Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes |
| Q51280414 | Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. |
| Q104751932 | Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials |
| Q37719462 | Benefits of twice-daily injection with insulin glargine: a case report and review of the literature |
| Q38597991 | Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes |
| Q36629558 | Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study |
| Q45118534 | Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin |
| Q60776984 | Bilateral lower limbs edema with “wooden” character induced by insulin glargine treatment |
| Q44379874 | Biotransformation of insulin glargine after subcutaneous injection in healthy subjects |
| Q81274707 | Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting |
| Q53673886 | Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation. |
| Q51130872 | Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine |
| Q95487956 | CADTH Canadian Drug Expert Committee Recommendation: Insulin Glargine and Lixisenatide (Soliqua — Sanofi-Aventis Canada Inc.): Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately |
| Q36541610 | Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. |
| Q85159795 | Cancer mortality and insulin glargine |
| Q33954827 | Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study |
| Q85182692 | Cancer risk in diabetic patients treated with insulin glargine? |
| Q35794125 | Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine |
| Q40197169 | Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). |
| Q92238765 | Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) |
| Q93273386 | Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis |
| Q50990888 | Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study. |
| Q92233564 | Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries |
| Q54975989 | Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials. |
| Q38607864 | Chronic Kidney Disease, Basal Insulin Glargine and Health Outcomes in People with Dysglycemia: the ORIGIN Study |
| Q35179893 | Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes |
| Q92270005 | Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial |
| Q34296834 | Clinical Experience with Insulin Glargine in Type 1 Diabetes |
| Q33732607 | Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine |
| Q98566704 | Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study |
| Q38971612 | Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. |
| Q95492061 | Clinical Review Report: Insulin glargine and lixisenatide injection (Soliqua): (Sanofi-Aventis): Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (l |
| Q50924825 | Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial |
| Q84891086 | Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID |
| Q35786400 | Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes |
| Q83305414 | Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance |
| Q84061339 | Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting |
| Q89230569 | Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study |
| Q87725490 | Clinical outcomes of switching from insulin glargine to NPH insulin in indigent patients at a charitable pharmacy: The Charitable Insulin NPH: Care for the Indigent study |
| Q37899645 | Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus |
| Q46214663 | Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus |
| Q93369439 | Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation |
| Q37331188 | Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. |
| Q83176024 | Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes |
| Q51298466 | Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. |
| Q37418681 | Combined randomised controlled trial experience of malignancies in studies using insulin glargine |
| Q34410616 | Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy |
| Q90915635 | Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine |
| Q90297958 | Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. |
| Q80518929 | Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir |
| Q92550049 | Comment on "a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes" |
| Q58393272 | Comment on Bordeleau et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366 |
| Q42466065 | Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366. |
| Q85942894 | Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346 |
| Q87567871 | Comment on: "Insulin glargine in a Brazilian state: should the government disinvest?" |
| Q43121314 | Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147. |
| Q55374453 | Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes. |
| Q43061107 | Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971. |
| Q92566991 | Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019 |
| Q89128434 | Comments on Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The Origin Study |
| Q83366700 | Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting |
| Q92391879 | Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study |
| Q54380726 | Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain. |
| Q54088300 | Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice. |
| Q27022065 | Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia |
| Q51021861 | Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy |
| Q49908914 | Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study |
| Q50103736 | Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials |
| Q77069300 | Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes |
| Q43991618 | Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus |
| Q36050662 | Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis |
| Q51769082 | Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. |
| Q28540655 | Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes |
| Q55097892 | Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients. |
| Q55347251 | Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial. |
| Q42358420 | Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol |
| Q38381899 | Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections |
| Q86115961 | Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice |
| Q51499735 | Comparison of breakfast and bedtime administration of insulin glargine in children and adolescents with Type 1 diabetes. |
| Q34119580 | Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes |
| Q54072039 | Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. |
| Q51388531 | Comparison of fasting capillary glucose variability between insulin glargine and NPH. |
| Q53094708 | Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study. |
| Q37105144 | Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes |
| Q51549873 | Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study. |
| Q84574109 | Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine |
| Q41832904 | Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial |
| Q43239421 | Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior |
| Q46707992 | Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy |
| Q43194901 | Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes |
| Q45946807 | Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. |
| Q89494400 | Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study |
| Q36817497 | Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies |
| Q51313434 | Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. |
| Q80802118 | Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin |
| Q39772332 | Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus |
| Q51494733 | Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. |
| Q34543057 | Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. |
| Q84701617 | Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial |
| Q38858785 | Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study. |
| Q43170918 | Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. |
| Q43052215 | Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes |
| Q91678321 | Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats |
| Q104286996 | Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats |
| Q43273069 | Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine |
| Q51362596 | Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. |
| Q51290322 | Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial. |
| Q53790905 | Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. |
| Q92348737 | Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy) |
| Q34423102 | Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy. |
| Q91901565 | Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: |
| Q38409647 | Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine |
| Q57951508 | Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes |
| Q44557905 | Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes |
| Q45956695 | Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. |
| Q57212874 | Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-dail |
| Q46521667 | Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs |
| Q38616958 | Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/ml using continuous glucose monitoring (CGM): A randomized crossover study |
| Q41586046 | Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly |
| Q45994653 | Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine. |
| Q51301509 | Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations. |
| Q44603989 | Computerized Generation of Circadian Sensor Modal Days with Continuous Glucose Monitoring for Comparison of Various Insulin Regimens Based on Insulin Glargine in Type 1 Diabetes |
| Q95372579 | Concentrated insulin glargine (Toujeo) for diabetes |
| Q37014889 | Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling |
| Q46686168 | Concomitant use of insulin glargine and NPH in type I diabetes |
| Q42703474 | Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan- |
| Q35772552 | Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study |
| Q45285681 | Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. |
| Q51304406 | Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. |
| Q47175820 | Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. |
| Q46060194 | Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine |
| Q42588795 | Controlled release of modified insulin glargine from novel biodegradable injectable gels. |
| Q52606010 | Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements. |
| Q51083162 | Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia |
| Q47260325 | Converting continuous insulin infusion to subcutaneous insulin glargine after cardiac surgery using percentage-based versus weight-based dosing: a pilot trial |
| Q92232985 | Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine |
| Q102132220 | Correction to: Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study |
| Q52672615 | Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes. |
| Q88116384 | Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables |
| Q94604308 | Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus |
| Q92067073 | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| Q60554936 | Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis |
| Q60556043 | Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis |
| Q91154258 | Correlation between Basal Insulin Glargine Dose Required in Achieving Target Fasting Blood Glucose and Various Clinical and Laboratory Parameters in Hospitalized Noncritical Patients |
| Q93138112 | Corrigendum to "Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population" [Nutr Metabol Cardiovasc Dis 29 (5) (May 2019) 496-503] |
| Q47698045 | Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece |
| Q34066485 | Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany |
| Q43005395 | Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada |
| Q43717999 | Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial |
| Q64064708 | Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA |
| Q55262528 | Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. |
| Q92043030 | Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial |
| Q58788707 | Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting |
| Q96820130 | Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia |
| Q96762578 | Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II |
| Q38970097 | Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies |
| Q47557627 | Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective |
| Q80253601 | Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland |
| Q37737461 | Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus |
| Q91322091 | Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes |
| Q82371964 | Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China |
| Q38815279 | Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China |
| Q87006980 | Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective |
| Q44456566 | Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. |
| Q91651264 | Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria |
| Q38709319 | Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. |
| Q39781917 | Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. |
| Q87646884 | Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus |
| Q45365045 | Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study |
| Q39993176 | Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. |
| Q46127637 | Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. |
| Q55231953 | DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. |
| Q37189266 | DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes |
| Q86887031 | Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database |
| Q47925155 | Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies |
| Q37288770 | Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus |
| Q44557853 | Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine |
| Q39421962 | Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. |
| Q88790594 | Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardio |
| Q94593658 | Development of a robust functional cell-based assay for replacing the rabbit blood sugar bioidentity test of insulin glargine drug substance |
| Q44050375 | Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus |
| Q42959216 | Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues |
| Q46497349 | Diabetes. Insulin glargine or rosiglitazone as add-on therapies. |
| Q84457793 | Diabetes: long-term use of insulin glargine might increase the risk of breast cancer |
| Q84402490 | Diabetic retinopathy and insulin glargine |
| Q89503871 | Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer |
| Q91219270 | Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars |
| Q46313054 | Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? |
| Q36976992 | Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected]. |
| Q39306199 | Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes |
| Q92950842 | Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec |
| Q51480351 | Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. |
| Q91529852 | Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes - a subanalysis from the BRIGHT trial |
| Q41656524 | Direct comparison of radioimmunoassay and LC-MS/MS for PK assessment of insulin glargine in clinical development. |
| Q46653652 | Disruption of KEX1 gene reduces the proteolytic degradation of secreted two-chain Insulin glargine in Pichia pastoris |
| Q45587323 | Distinct pharmacodynamics of insulin glargine and insulin detemir: Crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen |
| Q46872134 | Does a patient-administered titration algorithm of insulin glargine improve glycemic control? |
| Q45733357 | Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomiz |
| Q36560372 | Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases |
| Q50540970 | Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus |
| Q46740980 | Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. |
| Q42768876 | Dose accuracy and injection force of different insulin glargine pens |
| Q33932753 | Dose-response effects of insulin glargine in type 2 diabetes |
| Q36907851 | Dosing of insulin glargine in the treatment of type 2 diabetes |
| Q44767273 | Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis |
| Q58612828 | Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study |
| Q89128962 | Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial |
| Q37638873 | Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes |
| Q92688520 | Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial |
| Q37561045 | Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus |
| Q61774644 | Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的? |
| Q93157838 | EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS |
| Q26767164 | Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials |
| Q51839826 | Early hypoglycaemia after accidental intramuscular injection of insulin glargine. |
| Q64902522 | Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. |
| Q50351384 | Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes |
| Q80387846 | Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial |
| Q90636622 | Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study |
| Q49568487 | Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). |
| Q104143584 | Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs |
| Q91859685 | Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics |
| Q91297997 | Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial |
| Q38374620 | Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial |
| Q38374615 | Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial |
| Q38395267 | Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial |
| Q91723780 | Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial |
| Q64927892 | Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. |
| Q50198005 | Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial |
| Q37106424 | Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). |
| Q42445421 | Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs |
| Q33621821 | Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial |
| Q38609954 | Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. |
| Q92304184 | Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial |
| Q30490289 | Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes |
| Q84624812 | Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats |
| Q36600818 | Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine |
| Q43025106 | Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes |
| Q44665865 | Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes |
| Q93008530 | Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea |
| Q92117519 | Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS) |
| Q51311912 | Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up |
| Q90435580 | Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice |
| Q97641617 | Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study) |
| Q92428418 | Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting |
| Q58817760 | Effectiveness and safety of insulin glargine detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis |
| Q42498695 | Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit |
| Q36274368 | Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the P |
| Q35792427 | Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial |
| Q42509087 | Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes |
| Q90139905 | Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis |
| Q31082008 | Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis. |
| Q90857682 | Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting |
| Q57809857 | Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2) |
| Q98192648 | Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study |
| Q48210998 | Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial |
| Q35609223 | Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats |
| Q92615831 | Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults |
| Q38816480 | Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. |
| Q39180567 | Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial |
| Q64355373 | Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial |
| Q81294502 | Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6) |
| Q92771437 | Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice |
| Q46331361 | Effects of diet on glucose control in cats with diabetes mellitus treated with twice daily insulin glargine |
| Q33708984 | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
| Q57299522 | Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial |
| Q45285691 | Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes |
| Q35589774 | Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. |
| Q35921474 | Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study |
| Q34594675 | Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes |
| Q91627102 | Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes |
| Q51330863 | Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. |
| Q37468435 | Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus |
| Q43819853 | Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. |
| Q91968843 | Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial |
| Q51259906 | Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study. |
| Q46422628 | Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study |
| Q92950849 | Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2) |
| Q36786086 | Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes |
| Q91720325 | Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1) |
| Q55262674 | Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials. |
| Q33727441 | Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures |
| Q52605864 | Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. |
| Q51278923 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. |
| Q40955003 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial |
| Q28597145 | Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial |
| Q48263525 | Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). |
| Q91538668 | Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study |
| Q55046951 | Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis. |
| Q92064256 | Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis |
| Q88058591 | Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors |
| Q90856585 | Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (D |
| Q87310069 | Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study |
| Q40125071 | Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine |
| Q88688837 | Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial |
| Q88674677 | Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial |
| Q90971646 | Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study |
| Q91133256 | Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study |
| Q88362439 | Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study |
| Q93146501 | Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring |
| Q30847986 | Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials |
| Q51283779 | Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. |
| Q89461801 | Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial |
| Q91593993 | Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study |
| Q36730246 | Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension |
| Q54288492 | Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. |
| Q99416818 | Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial |
| Q89273744 | Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles |
| Q91663359 | Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial |
| Q37324757 | Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study |
| Q43225401 | Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan |
| Q42694248 | Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes |
| Q90842194 | Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes |
| Q91938340 | Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: |
| Q89772865 | Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L Randomized Clinical Tr |
| Q37596013 | Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study |
| Q37295993 | Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. |
| Q57210875 | Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial |
| Q53399727 | Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr |
| Q91208987 | Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial |
| Q50113279 | Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes |
| Q51293239 | Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. |
| Q64119481 | Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis |
| Q47446601 | Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study |
| Q46922036 | Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pi |
| Q46866724 | Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pi |
| Q88120199 | Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin |
| Q44745111 | Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy |
| Q46972556 | Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy |
| Q92752948 | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes |
| Q89162993 | Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements |
| Q46963636 | Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus |
| Q46050960 | Efficacy of insulin glargine in perioperative glucose control in type 2 diabetic patients |
| Q51354505 | Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. |
| Q48076623 | Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy |
| Q90856698 | Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study |
| Q51321978 | Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions. |
| Q37321746 | Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials |
| Q100406254 | Equipotency of insulin glargine 300 U/mL AND 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs |
| Q44739918 | Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion |
| Q42367201 | Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes |
| Q93607756 | Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats |
| Q42334007 | Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. |
| Q53485249 | Erratum to: Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. |
| Q92946941 | Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41:1672-1680 |
| Q53777921 | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Tri |
| Q55192252 | Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972 |
| Q94156353 | Evaluation of Unit Equivalency of Insulin Glargine to Insulin Detemir in an Acute Care Setting |
| Q50797123 | Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine |
| Q38073204 | Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir |
| Q86136303 | Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers |
| Q43280713 | Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting |
| Q36533328 | Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus |
| Q33700904 | Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. |
| Q53389588 | Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. |
| Q36897192 | Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom |
| Q46967505 | Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden |
| Q33791586 | Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies |
| Q55114408 | Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model. |
| Q74260762 | Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits |
| Q51489695 | Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. |
| Q42654585 | Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial |
| Q30688362 | Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. |
| Q91948780 | Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial |
| Q28277510 | Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial |
| Q40234430 | Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes |
| Q39959481 | Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. |
| Q90594027 | Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life |
| Q90123147 | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
| Q90683989 | Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL |
| Q44865710 | Fasting and insulin glargine in individuals with type 1 diabetes |
| Q36417783 | Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis |
| Q43288110 | Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes |
| Q46691043 | Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects |
| Q83874724 | Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine |
| Q35179836 | Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients |
| Q33932718 | Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study |
| Q100380093 | Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus GLP-1 RAs in people with type 2 diabetes mellitus: a network meta-analysis |
| Q44479625 | Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial |
| Q35210164 | Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis |
| Q35136457 | Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials |
| Q57456847 | GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes |
| Q89416395 | Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial |
| Q83019741 | Glucose control in acute myocardial infarction: a pilot randomized study controlled by continuous glucose monitoring system comparing the use of insulin glargine with standard of care |
| Q43167109 | Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration |
| Q40258044 | Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes |
| Q90021750 | Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment |
| Q48201978 | Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). |
| Q51470123 | Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. |
| Q47684311 | Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis). |
| Q58571337 | Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes |
| Q54209186 | Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-mo |
| Q50581167 | Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial |
| Q37308905 | Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e |
| Q89058653 | Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use |
| Q92184585 | Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study |
| Q47406914 | Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials |
| Q92313996 | Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials |
| Q91263744 | Glycemic Control in Adult Surgical Patients Receiving Regular Insulin Added to Parenteral Nutrition vs Insulin Glargine: A Retrospective Chart Review |
| Q62723603 | Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice |
| Q51278671 | Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. |
| Q46280280 | Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program |
| Q48637978 | Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design |
| Q45901075 | Glycemic control with use of insulin glargine after cardiothoracic surgery: a retrospective study. |
| Q45963931 | Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes. |
| Q48001064 | Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump |
| Q96611776 | Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study |
| Q45242372 | Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride |
| Q92613521 | Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus |
| Q46539973 | Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study |
| Q85289449 | HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea |
| Q92684714 | HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs |
| Q80496706 | Health care resource utilization and expenditures associated with the use of insulin glargine |
| Q43763782 | Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany |
| Q34042148 | Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review |
| Q42213808 | Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes |
| Q39624174 | High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. |
| Q92685940 | Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII) |
| Q102381614 | How many people with type 2 diabetes fulfil eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting? |
| Q45966175 | How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus. |
| Q36536807 | How much is too much? Outcomes in patients using high-dose insulin glargine |
| Q38784532 | Hypersensitivity Reaction to Insulin Glargine and Insulin Detemir in a Pediatric Patient: A Case Report |
| Q85886123 | Hypersensitivity reaction to a biosimilar insulin glargine |
| Q91787174 | Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting |
| Q58563432 | Hypoglycaemia as a function of HbA in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3 |
| Q89253596 | Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus |
| Q37119978 | Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials |
| Q92108622 | Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: a post hoc analysis of the EDITION 3 trial |
| Q41494572 | Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8 |
| Q36678706 | Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products |
| Q57300645 | IDEGLIRA IS ASSOCIATED WITH IMPROVED SHORT-TERM CLINICAL OUTCOMES AND COST SAVINGS COMPARED WITH INSULIN GLARGINE U100 PLUS INSULIN ASPART IN THE U.S |
| Q38738725 | IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting |
| Q47177813 | INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN, WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA, COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES. |
| Q89361478 | INSULIN GLARGINE 300 U/mL (TOUJEO®) |
| Q94130490 | INSULIN GLARGINE 300 U/ML VS. 100 U/ML IN OLDER PEOPLE WITH T2DM: RESULTS FROM A RANDOMIZED TRIAL |
| Q91682870 | Impact of Dosing Conversion From Basal Insulin to Follow-On Insulin Glargine |
| Q92566988 | Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal-Bolus Insulin: Phase 4 OPTIMIZE Study |
| Q45402509 | Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide |
| Q45746133 | Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin |
| Q90495792 | Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes |
| Q53573456 | Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. |
| Q48277301 | Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study |
| Q37626675 | Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials |
| Q95788090 | Importance of carbohydrate exposure before and after conversion from intravenous insulin therapy to subcutaneous administration of insulin glargine |
| Q57288400 | Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland |
| Q58738440 | Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program |
| Q35772567 | Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study |
| Q57298454 | Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study |
| Q91992004 | Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mL |
| Q37087031 | Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study |
| Q51347233 | Improved glycaemic control with insulin glargine as part of a basal-bolus regimen in T2DM patients inadequately controlled on premixed therapy. |
| Q46955572 | Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes |
| Q43115605 | Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. |
| Q45056461 | Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine |
| Q36097341 | Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes |
| Q46090848 | Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials. |
| Q46513423 | Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine |
| Q42398691 | Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec |
| Q90865860 | Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide |
| Q51485731 | Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine. |
| Q37199322 | Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine |
| Q89990683 | In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes |
| Q33321671 | In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. |
| Q88223094 | In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Met |
| Q36228964 | In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment |
| Q33537987 | In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites |
| Q37597568 | Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis |
| Q43286839 | Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine |
| Q43622665 | Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin |
| Q91422981 | Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies |
| Q46578347 | Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample |
| Q98664483 | Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin |
| Q45891791 | Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents |
| Q35800241 | Initiation of insulin glargine in children and adolescents with type 1 diabetes |
| Q43678513 | Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care |
| Q51465795 | Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. |
| Q46691040 | Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial |
| Q43110605 | Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs |
| Q54857875 | Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. |
| Q64904305 | Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. |
| Q91775324 | Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? |
| Q92412266 | Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice |
| Q38715053 | Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus |
| Q51245623 | Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response. |
| Q92129860 | Insulin Glargine Dose and Weight Changes in Underweight, Normal Weight, and Overweight Children Newly Diagnosed with Type 1 Diabetes Mellitus |
| Q38754477 | Insulin Glargine U-300 (Toujeo®): A Review |
| Q92427862 | Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4 |
| Q92901758 | Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study |
| Q93147671 | Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes |
| Q44027980 | Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy |
| Q93033487 | Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing |
| Q39408293 | Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes |
| Q94857038 | Insulin Glargine: a review 8 years after its introduction |
| Q34421048 | Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. |
| Q52611423 | Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes. |
| Q92334626 | Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? |
| Q33607759 | Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial |
| Q42382362 | Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials |
| Q34691408 | Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical |
| Q36629179 | Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. |
| Q58868129 | Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy |
| Q34583341 | Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. |
| Q90856746 | Insulin degludec is associated with less frequent and milder hypoglycemia in insulin-deficient patients with type 1 diabetes compared with insulin glargine or detemir |
| Q37374117 | Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study |
| Q36158944 | Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. |
| Q26800254 | Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials |
| Q47927613 | Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables |
| Q36426912 | Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) |
| Q34726423 | Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials |
| Q90856510 | Insulin degludec versus insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 tr |
| Q42694005 | Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial |
| Q34269828 | Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria |
| Q34269834 | Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria |
| Q33835638 | Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. |
| Q49174475 | Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes |
| Q95598678 | Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL |
| Q42062228 | Insulin detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin. |
| Q47294978 | Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT |
| Q81906445 | Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial |
| Q24235596 | Insulin detemir versus insulin glargine for type 2 diabetes mellitus |
| Q34507672 | Insulin glargine |
| Q73231951 | Insulin glargine |
| Q73578513 | Insulin glargine |
| Q74301094 | Insulin glargine |
| Q33220508 | Insulin glargine (Aventis Pharma). |
| Q44184491 | Insulin glargine (HOE901) |
| Q59624506 | Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety |
| Q84442403 | Insulin glargine (Lantus) and cancer risk |
| Q74322664 | Insulin glargine (Lantus), a new long-acting insulin |
| Q34776146 | Insulin glargine (Lantus). |
| Q92116334 | Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues |
| Q33884391 | Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus |
| Q28074690 | Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives |
| Q96350337 | Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial |
| Q38765011 | Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus |
| Q89939767 | Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes |
| Q46815969 | Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). |
| Q55385002 | Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats. |
| Q42730599 | Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice |
| Q84939030 | Insulin glargine and cancer |
| Q34320632 | Insulin glargine and cancer risk in patients with diabetes: a meta-analysis |
| Q84205739 | Insulin glargine and cancer--an unsubstantiated allegation |
| Q84409901 | Insulin glargine and cancer: another side to the story? |
| Q46922061 | Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain |
| Q37106445 | Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes |
| Q42793469 | Insulin glargine and incidence of cancer--an ongoing debate |
| Q54440127 | Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells. |
| Q36521871 | Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus |
| Q58053452 | Insulin glargine and its role in glycaemic management of Type 2 diabetes |
| Q38636682 | Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies |
| Q39361047 | Insulin glargine and malignancy: an unwarranted alarm |
| Q36964626 | Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes |
| Q35714366 | Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database |
| Q34366858 | Insulin glargine and risk of cancer: a meta-analysis |
| Q83181612 | Insulin glargine and the risk of cancer |
| Q51482087 | Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. |
| Q80506862 | Insulin glargine clinical trials |
| Q34663438 | Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients |
| Q91865933 | Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis |
| Q83578570 | Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics |
| Q50976335 | Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. |
| Q42593354 | Insulin glargine controversy: a tribute to the editorial team at Diabetologia. |
| Q51349497 | Insulin glargine dosing before next-day surgery: comparing three strategies. |
| Q33769611 | Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease |
| Q45018475 | Insulin glargine for type 2 diabetes. |
| Q46429410 | Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats |
| Q46879696 | Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes |
| Q46754870 | Insulin glargine improves glycaemic control after coronary surgery in patients with diabetes or pre-diabetes |
| Q56994664 | Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes |
| Q48487507 | Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis |
| Q79343771 | Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes |
| Q38175354 | Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review |
| Q95531336 | Insulin glargine in children aged 2 to 5 years |
| Q79769954 | Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial |
| Q46881795 | Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus |
| Q78290567 | Insulin glargine in continuous enteric tube feeding |
| Q53286677 | Insulin glargine in enteric tube feeding. |
| Q79575474 | Insulin glargine in patients with severe hepato-gastroenterology diseases and hyperglycemia receiving parenteral nutrition |
| Q51322375 | Insulin glargine in pediatric patients with type 1 diabetes in Japan. |
| Q34449820 | Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. |
| Q36012923 | Insulin glargine in the treatment of type 1 and type 2 diabetes |
| Q37199311 | Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience |
| Q43250198 | Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: an experience of 4 cases |
| Q44655136 | Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. |
| Q46584331 | Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal |
| Q38426608 | Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study |
| Q46926372 | Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study |
| Q83201132 | Insulin glargine or neutral protamine Hagedorn in patients with severe insulin resistance: Is there a benefit? |
| Q36527716 | Insulin glargine overdose |
| Q46195706 | Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. |
| Q35565342 | Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress |
| Q33556840 | Insulin glargine safety in pregnancy: a transplacental transfer study |
| Q80348060 | Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children |
| Q51294479 | Insulin glargine treatment of a ferret with diabetes mellitus. |
| Q37154820 | Insulin glargine use and breast cancer risk: Associations with cumulative exposure |
| Q61852772 | Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation |
| Q51577217 | Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation. |
| Q61852798 | Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden |
| Q37879778 | Insulin glargine use during pregnancy |
| Q35618989 | Insulin glargine versus NPH insulin in patients with type 1 diabetes |
| Q42599596 | Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients |
| Q31040955 | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India |
| Q46511255 | Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus |
| Q37315640 | Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy |
| Q35019233 | Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma |
| Q51355802 | Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. |
| Q46915981 | Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies |
| Q73813051 | Insulin glargine. Glargine, HOE 71GT15, HOE 71GT80, HOE 901 |
| Q97675506 | Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis |
| Q93024996 | Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia |
| Q91423655 | Insulin glargine: a basal insulin for the management of diabetes |
| Q36081459 | Insulin glargine: a long acting insulin analog |
| Q44661406 | Insulin glargine: a long-acting insulin for diabetes mellitus. |
| Q34648626 | Insulin glargine: a new basal insulin |
| Q34976162 | Insulin glargine: a new basal insulin analogue |
| Q34594713 | Insulin glargine: a new long-acting insulin product. |
| Q35144069 | Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus |
| Q35886868 | Insulin glargine: a reevaluation of rodent carcinogenicity findings |
| Q34093019 | Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus |
| Q35177665 | Insulin glargine: a systematic review of a long-acting insulin analogue |
| Q35194343 | Insulin glargine: an updated review of its use in the management of diabetes mellitus |
| Q77911757 | Insulin glargine: basal insulin of choice? |
| Q94333146 | Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes |
| Q37199301 | Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction |
| Q35637296 | Insulin glargine: long-acting basal insulin analog for improved metabolic control |
| Q51514519 | Insulin glargine: the first clinically useful extended-acting insulin in half a century? |
| Q34515529 | Insulin glargine: the first clinically useful extended-action insulin analogue |
| Q34543042 | Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial |
| Q45927867 | Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial. |
| Q37263232 | Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial |
| Q37199318 | Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine |
| Q44110599 | Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine |
| Q37199315 | Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine |
| Q79474065 | Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US |
| Q35807316 | Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue |
| Q92136201 | Insulin/carbohydrates ratio during the first 6-month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study |
| Q37113227 | Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice |
| Q41661396 | Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). |
| Q46098661 | Intentional overdose with insulin glargine |
| Q35998015 | Intentional overdose with insulin glargine and insulin aspart |
| Q36682344 | Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir |
| Q46264161 | Intravenous overdose of insulin glargine without prolonged hypoglycemic effects |
| Q46223953 | Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs |
| Q34543063 | Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml |
| Q41906566 | Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India |
| Q92883922 | Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population |
| Q38715043 | Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. |
| Q49899858 | LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels |
| Q49720592 | LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes |
| Q51556027 | Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. |
| Q51554477 | Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. |
| Q90694563 | Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease |
| Q61807531 | Lilly Insulin Glargine Versus Lantus in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5) |
| Q92233754 | Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study |
| Q51597934 | Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials. |
| Q37650588 | Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature |
| Q100509708 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial |
| Q37348811 | Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial |
| Q57810137 | Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD |
| Q39657472 | Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus |
| Q93008678 | Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China |
| Q39933652 | Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. |
| Q53676267 | Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. |
| Q51292483 | Long-acting insulin analogues (insulin glargine or determir) and continuous subcutaneous insulin infusion in the treatment of type 1 diabetes mellitus in the paediatric population. |
| Q91538572 | Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16) |
| Q82037910 | Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting |
| Q57160154 | Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US |
| Q39586526 | Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. |
| Q79448251 | Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study |
| Q38438554 | Long-term effects of insulin glargine on the risk of breast cancer |
| Q46901784 | Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). |
| Q46910692 | Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice |
| Q46660456 | Long-term glycaemic control with insulin glargine in Type 2 diabetes |
| Q50861260 | Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine |
| Q35044151 | Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. |
| Q91755952 | Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study |
| Q92027875 | Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes |
| Q85452010 | Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin |
| Q89162669 | Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone |
| Q36361469 | Low within- and between-day variability in exposure to new insulin glargine 300 U/ml |
| Q37106509 | Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta |
| Q51375890 | Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. |
| Q96221644 | Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials |
| Q54651646 | Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. |
| Q44181331 | Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy |
| Q85711459 | Lower limbs edema by insulin glargine treatment: two other cases in pediatrics |
| Q92495423 | Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2 |
| Q34468769 | Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study |
| Q37058021 | Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. |
| Q44909481 | Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes |
| Q39231523 | MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation. |
| Q90676746 | MYL1501D Insulin Glargine: A Review in Diabetes Mellitus |
| Q48712623 | Management of intentional overdose of insulin glargine |
| Q44867566 | Medication of the month. Insulin glargine (Lantus) |
| Q34782893 | Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study |
| Q93090721 | Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China |
| Q35996906 | Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy |
| Q33637807 | Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine |
| Q103733427 | Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study |
| Q42974944 | Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue |
| Q43488672 | Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting |
| Q83416094 | Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting |
| Q36426750 | Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes |
| Q87852806 | Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide |
| Q96607655 | Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi) |
| Q37395476 | Mitogenic potency of insulin glargine. |
| Q83219949 | Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus |
| Q92439926 | Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes |
| Q44454238 | Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis |
| Q79865927 | Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada |
| Q34808296 | Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes |
| Q90926497 | More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial |
| Q79810973 | More from PHARMAC on long-acting insulin analogues: insulin glargine now funded |
| Q60707174 | More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L |
| Q46123887 | More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus |
| Q45932507 | Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. |
| Q82662546 | Multiple daily insulin regimen using insulin glargine in type 1 diabetic Saudi children |
| Q42484838 | Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes |
| Q33869943 | Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus |
| Q104470254 | Needle-free jet injection of insulin glargine improves glycaemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system |
| Q46963862 | Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit |
| Q38559945 | New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus |
| Q53211985 | New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). |
| Q31097676 | New Meta-Analysis of Patient-Level Data on Efficacy And Hypoglycaemia with Insulin Glargine or Nph Insulin in Type 2 Diabetes Mellitus (T2DM) According to Concomitant Oral Therapy |
| Q35538347 | New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). |
| Q37343841 | New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). |
| Q37343847 | New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). |
| Q87643980 | New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1 |
| Q44485772 | New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). |
| Q35240456 | New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). |
| Q80109598 | No apparent alteration of F-18 FDG biodistribution when injected shortly after insulin glargine |
| Q73215400 | No evidence for accumulation of insulin glargine (LANTUS) |
| Q44024472 | No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes |
| Q92188767 | Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL |
| Q46494700 | Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes |
| Q51369983 | Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. |
| Q38767461 | Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes |
| Q54159731 | Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union. |
| Q46001828 | Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. |
| Q85254774 | ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use |
| Q84463123 | Observational registry database studies link insulin glargine with cancer risk |
| Q87234696 | Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine |
| Q86776650 | Octreotide for the treatment of hypoglycemia after insulin glargine overdose |
| Q28287325 | Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial |
| Q46675368 | Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial |
| Q45127422 | Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes |
| Q43263307 | Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. |
| Q46176820 | Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study |
| Q43685855 | Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility |
| Q44976604 | Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes |
| Q80544940 | Once-daily insulin glargine versus 6-hour sliding scale regular insulin for control of hyperglycemia after a bariatric surgical procedure: a randomized clinical trial |
| Q48264152 | Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study |
| Q90708905 | Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c |
| Q36366198 | One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten |
| Q24656644 | One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial |
| Q43056507 | One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress |
| Q49365317 | Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes |
| Q46892322 | Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times |
| Q46085959 | Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study |
| Q46401183 | Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. |
| Q46610518 | Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine |
| Q44615064 | Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations. |
| Q44492858 | Optimizing glycemic control with insulin glargine |
| Q35563702 | Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction |
| Q91504881 | Optimizing treatment strategies with insulin glargine in Type 2 diabetes |
| Q90608094 | Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life |
| Q36645386 | Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain |
| Q40786289 | PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. |
| Q83317118 | Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine |
| Q97547876 | Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study |
| Q51027438 | Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study |
| Q39018098 | Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy |
| Q36366184 | Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes |
| Q47374326 | Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). |
| Q93034166 | Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes |
| Q35126645 | Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes |
| Q36432159 | Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice |
| Q43863683 | Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin |
| Q83661009 | Perinatal outcomes in pregnancies managed with antenatal insulin glargine |
| Q46686827 | Perioperative glycemic control by insulin glargine in type 2 diabetic patients |
| Q30244827 | Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes |
| Q88515691 | Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs |
| Q43012919 | Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats |
| Q95491516 | Pharmacoeconomic Review Report: Insulin glargine + lixisenatide (Soliqua): (Sanofi-Aventis): Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less |
| Q46701751 | Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique |
| Q91275693 | Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus |
| Q30248803 | Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance |
| Q86352001 | Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes |
| Q45729286 | Pharmacokinetics and pharmacodynamics of insulin glargine-insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals |
| Q43275328 | Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes |
| Q55033955 | Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. |
| Q57283509 | Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes |
| Q51159599 | Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes |
| Q73558047 | Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine |
| Q48127212 | Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). |
| Q41825022 | Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes |
| Q46498115 | Poisoning with insulin glargine |
| Q64064432 | Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world |
| Q91257295 | Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| Q46805425 | Potential flaws and biases in a randomized controlled trial (RCT) of insulin determir vs. insulin glargine by Pieber and colleagues. |
| Q34368864 | Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis |
| Q51284082 | Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. |
| Q84539770 | Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial |
| Q51499382 | Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. |
| Q90298250 | Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study |
| Q90856530 | Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan |
| Q51313546 | Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. |
| Q91874675 | Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and OPtimisation (TOP) registry |
| Q33251163 | Preliminary data of insulin glargine use among Thai adolescents and young adults with type 1 diabetes mellitus treated at Siriraj Hospital. |
| Q54505440 | Premixed Insulin Lispro Versus Insulin Glargine In Type 2 Diabetes: A Meta-Analysis. |
| Q50803928 | Prescription of insulin glargine in primary care practices in Germany |
| Q88866316 | Prevalence of insulin glargine vial use beyond 28 days in a Medicaid population |
| Q35076942 | Primary culturing and effects of insulin glargine on proliferation, differentiation of human preadipocytes from subcutaneous and omental adipose tissue |
| Q40006372 | Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine |
| Q58456995 | Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes |
| Q44666302 | Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients |
| Q40899690 | Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: a pilot study |
| Q82231960 | Putting insulin glargine and malignancies into perspective |
| Q46660208 | Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes |
| Q80014242 | Question: is insulin glargine more effective? |
| Q50207153 | Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. |
| Q50570104 | Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial). |
| Q51582826 | Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and |
| Q44333547 | Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens |
| Q41673841 | Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. |
| Q41673741 | Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. |
| Q64282776 | Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study |
| Q38833204 | Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used |
| Q94461210 | Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project |
| Q33515774 | Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. |
| Q80238826 | Re: Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US |
| Q84088689 | Re: trial comparing insulin detemir with insulin glargine |
| Q37207121 | Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine |
| Q96301517 | Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018) |
| Q36057429 | Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus |
| Q98205690 | Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland |
| Q89618443 | Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar) |
| Q93136922 | Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study |
| Q98718225 | Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study) |
| Q47259503 | Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin. |
| Q36809906 | Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study |
| Q37225390 | Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs |
| Q92181160 | Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus |
| Q43861054 | Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies |
| Q94492578 | Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: the observational ORION study |
| Q47770450 | Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin |
| Q97587987 | Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study |
| Q42465439 | Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism |
| Q30438126 | Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine |
| Q46406475 | Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes |
| Q44681492 | Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin |
| Q39533256 | Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials |
| Q46082135 | Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes |
| Q46129839 | Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials |
| Q81222368 | Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes |
| Q46153484 | Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes |
| Q41540115 | Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study) |
| Q37418019 | Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes. |
| Q37815511 | Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir |
| Q94664167 | Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin and dapagliflozin |
| Q46340066 | Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan |
| Q41322679 | Replacement of the CysA7-CysB7 disulfide bond with a 1,2,3-triazole linker causes unfolding in insulin glargine |
| Q41145313 | Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction |
| Q83185342 | Request for clarification from Ruiter et al regarding 'Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study' |
| Q93546629 | Request for clarification from Ruiter et al regarding ‘Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study’. Reply to Carstensen |
| Q46007489 | Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. |
| Q50864592 | Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346. |
| Q43121281 | Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147. |
| Q46360171 | Response to Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. Diabetes Care 2011;34:1965–1971. |
| Q42466072 | Response to Suissa and Azoulay. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366. |
| Q42466083 | Response to Zanders et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366. |
| Q90684268 | Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? |
| Q39080234 | Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine |
| Q37799577 | Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities |
| Q35587424 | Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study |
| Q37811677 | Risk of cancer in patients receiving insulin glargine |
| Q91544384 | Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100 |
| Q46605831 | Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin |
| Q46436723 | Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy: comparison of insulin glargine with NPH insulin as basal insulin supplement |
| Q92956760 | Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial |
| Q104570329 | Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study) |
| Q90919337 | Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study |
| Q64984140 | SUN-160 Insulin Glargine Time of Injection during Fasting Ramadan in Patients with Type 1 Diabetes. |
| Q55484352 | Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Rand |
| Q88447763 | Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately |
| Q90271659 | Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus |
| Q89571957 | Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial |
| Q50673132 | Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus |
| Q44488975 | Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients |
| Q28078467 | Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis |
| Q41831179 | Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks |
| Q73328507 | Safety of insulin glargine |
| Q37826022 | Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis |
| Q89754325 | Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial |
| Q43082775 | Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes |
| Q42689621 | Short Term Efficacy and Safety of Insulin Glargine in Type 2 Diabetes Inadequately Controlled with Single or Two Oral Agents: A Prospective, Open Label Study |
| Q87370307 | Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes |
| Q88946729 | Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation |
| Q87223934 | Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 |
| Q93194011 | Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus |
| Q37296843 | Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study |
| Q46884452 | Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]. |
| Q42383447 | Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial |
| Q43074672 | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| Q42968125 | Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans |
| Q44512290 | Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects |
| Q35127583 | Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes |
| Q36822640 | Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes |
| Q36070262 | Spotlight on insulin glargine in type 1 and 2 diabetes mellitus |
| Q79370979 | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride |
| Q42668700 | Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels |
| Q51945347 | Study of the aggregation of insulin glargine by light scattering. |
| Q79809136 | Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women |
| Q81363092 | Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes? |
| Q91565329 | Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes |
| Q45398614 | Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial |
| Q51068494 | Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). |
| Q33732588 | Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients |
| Q42671430 | Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system |
| Q89415279 | Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries |
| Q93242372 | Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study |
| Q54985686 | Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. |
| Q86115974 | Switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes |
| Q45911578 | Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. |
| Q46119624 | Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study |
| Q88342898 | Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? |
| Q91540754 | Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3) |
| Q87462719 | Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients |
| Q35938675 | Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine |
| Q38317168 | Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus |
| Q51060984 | Systematic review with meta-analysis: Subcutaneous insulin glargine coadministration for diabetic ketoacidosis |
| Q47728089 | TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. |
| Q92238848 | Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes |
| Q45295447 | Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial |
| Q89239074 | The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes - An Analysis From The Swedish Health Care Perspective |
| Q37404238 | The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes |
| Q36319194 | The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. |
| Q91762825 | The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control |
| Q92717557 | The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus |
| Q89239059 | The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective |
| Q35239776 | The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol. |
| Q90290375 | The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling |
| Q42454877 | The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia |
| Q45902935 | The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. |
| Q47674144 | The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications |
| Q45050904 | The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine |
| Q50092178 | The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan |
| Q43878313 | The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain |
| Q39645469 | The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes |
| Q37199327 | The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics |
| Q50732301 | The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial |
| Q53771761 | The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes. |
| Q48165783 | The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. |
| Q53173262 | The effect of insulin glargine and nutritional model on metabolic control, quality of life and behavior in children and adolescents with type 1 diabetes mellitus. |
| Q97682127 | The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel |
| Q33771752 | The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes |
| Q36391138 | The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice |
| Q36720304 | The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i |
| Q50224760 | The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial |
| Q26999454 | The evolution of insulin glargine and its continuing contribution to diabetes care |
| Q43090841 | The highest (3600 IU) reported overdose of insulin glargine ever and management |
| Q45146650 | The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study |
| Q50733796 | The insulin glargine dilemma: an opportunity for the diabetes community? |
| Q33442343 | The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients |
| Q46764130 | The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice |
| Q84367711 | The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings |
| Q88803321 | The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting |
| Q86945647 | The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation |
| Q87414313 | The outcome of care in people with type 1 diabetes after switching to insulin glargine-based regimens in a real-life setting: a long-term observational study |
| Q92383216 | The quaternary structure of insulin glargine and glulisine under formulation conditions |
| Q46866703 | The rate of improvement in metabolic control in children with diabetes mellitus type 1 on insulin glargine depends on age. |
| Q92428589 | The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL |
| Q51392679 | The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. |
| Q38779849 | The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus |
| Q82411520 | The use of insulin glargine with gestational diabetes mellitus |
| Q33709306 | The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. |
| Q44955647 | The utility of insulin glargine in the treatment of diabetes mellitus |
| Q33609788 | Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once-daily injection of insulin glargine in non-obese diabetic mice |
| Q40342309 | Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus |
| Q46818618 | Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. |
| Q51941134 | Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. |
| Q46673041 | Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes |
| Q73840622 | Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo |
| Q44606779 | Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. |
| Q100407898 | Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus |
| Q64926007 | Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. |
| Q48722645 | Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). |
| Q92160626 | Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study |
| Q46978232 | To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1 |
| Q46834147 | Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial |
| Q79948756 | Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data |
| Q87349210 | Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes |
| Q47192711 | Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study |
| Q45919761 | Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin. |
| Q47402182 | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| Q36755470 | Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals |
| Q36063814 | Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate. |
| Q34563147 | Treatment of transient neonatal diabetes mellitus: insulin pump or insulin glargine? Our experience |
| Q74503309 | Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes |
| Q58040220 | Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study |
| Q80869843 | Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes |
| Q100496088 | Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study |
| Q54551772 | Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. |
| Q39732794 | Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells |
| Q79911035 | Treatment with insulin glargine does not suppress serum IGF-1 |
| Q51470109 | Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. |
| Q51314770 | Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial. |
| Q46966714 | Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients |
| Q79143510 | Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al |
| Q74530226 | Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report |
| Q46397874 | Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes |
| Q80119501 | Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart |
| Q60960407 | Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus |
| Q35115119 | Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring |
| Q83630346 | Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes |
| Q33865511 | Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). |
| Q55402139 | U300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes. |
| Q46719017 | Unintentional overdose of insulin glargine |
| Q90292340 | Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review |
| Q61684850 | Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women |
| Q88248538 | Use of Insulin Glargine in the Management of Neonatal Hyperglycemia in an ELBW Infant |
| Q45955053 | Use of a temporary "solubilizing" peptide tag for the Fmoc solid-phase synthesis of human insulin glargine via use of regioselective disulfide bond formation. |
| Q82495745 | Use of insulin detemir and insulin glargine during pregnancy: are the data convincing? |
| Q37296839 | Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group |
| Q88083213 | Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group |
| Q73821410 | Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes |
| Q81242128 | Use of insulin glargine during pregnancy |
| Q74181563 | Use of insulin glargine during pregnancy in a type 1 diabetic woman |
| Q81266236 | Use of insulin glargine during pregnancy in seven type 1 diabetic women |
| Q79683832 | Use of insulin glargine during pregnancy: a case-control pilot study |
| Q80550593 | Use of insulin glargine in Japanese patients with type 1 diabetes |
| Q53284660 | Use of insulin glargine in children under age 6 with type 1 diabetes. |
| Q56983527 | Use of insulin glargine in dogs with diabetes mellitus |
| Q46871371 | Use of insulin glargine in patients with hyperglycaemia receiving artificial nutrition |
| Q43247406 | Use of insulin glargine in type 1 diabetes children with less than eight years old |
| Q47844001 | Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes |
| Q64066550 | Utilising a milk-based meal replacement programme in a bariatric patient with poorly controlled type 2 diabetes mellitus |
| Q104563353 | Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study |
| Q91432106 | Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups |
| Q91364563 | When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control |
| Q84424818 | Where now for insulin glargine--a time for pragmatic medicine? |
| Q38721614 | Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. |
| Q51434296 | [A study of variability in glycaemia in children and adolescents with diabetes mellitus type 1 on treatment with insulin glargine] |
| Q81153988 | [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success] |
| Q84146791 | [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutor |
| Q51314604 | [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)]. |
| Q91824178 | [Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)] |
| Q51469207 | [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy]. |
| Q88211449 | [Comparison of two insulin glargine formulations: biosimilar vs. reference product] |
| Q84480625 | [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus] |
| Q45995136 | [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. |
| Q73916115 | [Delayed action insulins. What is the value of insulin glargine in general practice?] |
| Q90458575 | [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective] |
| Q90216450 | [Improvement in the glycaemic control of patients after switching from human insulin to insulin glargine-based basal-bolus regimen] |
| Q84963250 | [Insulin glargine and cancer: a storm in a glass of water?] |
| Q79913798 | [Insulin glargine in intensively-treated type 1 diabetes mellitus] |
| Q80461829 | [Insulin glargine--a systematic review of clinical studies. No documented advantages with Lantus compared to NPH insulin] |
| Q54323833 | [Insulin glargine. The most studied basal insulin]. |
| Q91820282 | [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union] |
| Q81516822 | [Lipoatrophy after use of long acting insulin glargine analogue in a 32-year-old patient with type 1 diabetes] |
| Q81753960 | [Long acting insulin analogues: results of clinical studies with insulin glargine] |
| Q82273093 | [Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine] |
| Q51274182 | [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic]. |
| Q95510848 | [Prolonged hypoglycemia caused by overdose of insulin glargine and human insulin] |
| Q43485194 | [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESO |
| Q51310281 | [Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen]. |
| Q52836101 | [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE]. |
| Q38711727 | iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. |
| Q88722051 | iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes |
| Q28077366 | rDNA insulin glargine U300 - a critical appraisal |
| Arabic (ar / Q13955) | إنسولين غلارجين | wikipedia |
| cy | Inswlin Glargin | wikipedia |
| Insulin glargin | wikipedia | |
| Insulin glargine | wikipedia | |
| en-simple | Insulin glargine | wikipedia |
| Insulina glargina | wikipedia | |
| Persian (fa / Q9168) | انسولین گلارژین | wikipedia |
| Glargiini-insuliini | wikipedia | |
| Insuline glargine | wikipedia | |
| Insulina glargine | wikipedia | |
| インスリン グラルギン | wikipedia | |
| 인슐린 글라진 | wikipedia | |
| Insuline glargine | wikipedia | |
| or | ଇନସୁଲିନ ଗ୍ଲାର୍ଜିନ | wikipedia |
| Insulina glargine | wikipedia | |
| Insulină glargin | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Insulin glargin | wikipedia |
| Insulin glargin | wikipedia | |
| Insulin glargine | wikipedia | |
| 甘精胰島素 | wikipedia |
Search more.